Injectable testosterone is associated with a higher short-term risk of cardiovascular events compared with testosterone gel or patch formulations, according to a new epidemiologic study of three large ...
Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events. The Food and Drug Administration (FDA) has approved ...
The Food and Drug Administration (FDA) has, for the third time, declined approval of the long-acting testosterone undecanoate injection product (Aveed, Endo Pharma Solutions) for the treatment of men ...
A study published in the Journal of the American Medical Association found that injectable testosterone results in fewer cardiovascular adverse events than gel- or patch-based formulations, offering ...
New Delhi, Jun 21 (PTI) Drug firm Cipla today said it has received final nod from the US health regulator for generic Testosterone Cypionate injection used for replacement therapy in males for ...
Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events. The Food and Drug Administration (FDA) has approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback